SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that the last patient in the Company's Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person Phase 2 clin ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from XXXXXXXX XX, XXXX to XXXXXXXX XX, XXXX Commission File Number: 001-35610 | --- | --- | |------------------------------------------------------------------------ ...

Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks • Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) • Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024— Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced financial results for the fiscal qu ...

Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clin ...

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ:ACAD), for example. Back in 2011, the biotech was just developing its treatment of Parkinson’s disease psychosis and traded at just 70 cents. By 2015, it was at $51.24.Or, look at Advanced Micro Devices (NASDAQ:AMD). In 2015, it traded at about $1.99. Today, thanks to the artificial intelligence and semiconductor boom, it hit a hit of $214.81.Each had incredible growth stories tha ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] Group 2 - The company specializes in various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [2] - Proactive adopts technology enthusiastically, utilizing decades of expertise and experience among its content creators [2] - Automation and software tools, including generative AI, are occasionally used, but all content is edited and authored by humans [3]

Core Insights - Atossa Therapeutics supports new USPSTF guidelines recommending breast cancer screening for women starting at age 40, addressing rising breast cancer rates and disparities in diagnosis and mortality [1][2][4] Group 1: Guidelines and Impact - The updated guidelines suggest biennial mammography screening for women aged 40 to 74, responding to increased breast cancer rates among younger women and racial disparities [2] - The guidelines are set to take effect ahead of a September 2024 FDA deadline for mammogram facilities to provide detailed breast density information, which is a significant risk factor for breast cancer [2] Group 2: Company Initiatives - Atossa is evaluating its lead asset, (Z)-endoxifen, in five Phase 2 clinical trials, including a study focused on reducing mammographic breast density in premenopausal women [3][6] - The company emphasizes the importance of developing therapies to prevent breast cancer, noting that women with dense breast tissue are five times more likely to develop the disease [4] Group 3: Product Details - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that not only inhibits estrogen receptors but also degrades them, showing efficacy in patients resistant to other hormonal treatments [5] - Atossa is developing an oral formulation of (Z)-endoxifen that bypasses liver metabolism and stomach acidity, demonstrating good tolerance in early studies [6] Group 4: Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on innovative oncology medicines, particularly in breast cancer prevention and treatment [7]

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The expanded research agreement with Weill Cornell will build ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...